Expression of FOXP1 and colorectal cancer prognosis

Laboratory Medicine

Volumn 46, Issue 4, 2015, Pages 299-311

  De Smedt, Linde ^a   Palmans, Sofie ^a   Govaere, Olivier ^a   Moisse, Matthieu ^b,c   Boeckx, Bram ^b,c   De Hertogh, Gert ^b,c   Prenen, Hans ^d   Van Cutsem, Erik ^d   Tejpar, Sabine ^d   Tousseyn, Thomas ^a,d   Sagaert, Xavier ^a,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cancer research; Colorectal cancer; FOXP1; Immunohistochemistry; Prognosis; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLORECTAL CANCER; CORRELATIONAL STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RNA SEQUENCE; SURVIVAL RATE; CHEMISTRY; COLON; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; COLON; COLORECTAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES;

EID: 84949812591     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LM7IHV2NJI1PHMXC     Document Type: Article

References (46)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DB. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4(10):769-780.
3. Ferguson LR. Recent advances in understanding of interactions between genes and diet in the etiology of colorectal cancer. World J Gastrointest Oncol. 2010;2(3):125-129.
4. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J Nutr. 2007;137(11 Suppl):2576S-2579S.
5. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916-932.
6. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8(12):686-700.
7. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67(3):253-256.
8. Vrieling A, Kampman E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr. 2010;92(3):471-490.
9. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol. 2002;17(1):17-26
10. Shu W, Yang H, Zhang L, Lu MM, Morrisey EE. Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem. 2001;276(29):27488-27497.
11. Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001;61(24):8820-8829
12. Li S, Weidenfeld J, Morrisey EE. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol. 2004;24(2):809-822.
13. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007;11(7):955-965.
14. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol. 2006;7(8):819-826.
15. Dasen JS, De Camilli A, Wang B, et al. Hox repertoires for motor neuron diversity and connectivity gated by a single accessory factor, FoxP1. Cell. 2008;134(2):304-316.
16. Han SL, Wu XL, Wan L, Zeng GG, Li JL, Liu Z. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig Surg. 2009;26(2):156-162.
17. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2005;11(3):1065-1072.
18. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia. 2005;19(8):1299-1305.
19. Barrans SL, Fenton JAL, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood. 2004;104(9):2933-2935.
20. Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490-2497.
21. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138(2):230-235.
22. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Mod Pathol. 2006;19(1):9-16.
23. Banham AH, Boddy J, Launchbury R, et al. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate. 2007;67(10):1091-1098.
24. Fox SB, Brown P, Han C, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor α and improved survival in primary human breast carcinomas. Clin Cancer Res. 2004;10(10):3521-3527.
25. Ijichi N, Shigekawa T, Ikeda K, et al. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer. 2012;3(4):147-159..
26. Brown PJ, Ashe SL, Leich E, et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood. 2008;111(5):2816-2824.
27. Courts C, Brunn A, Montesinos-Rongen M, et al. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol. 2009;68(9):972-976.
28. Govaere O, Komuta M, Berkers J, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014;63(4):674-685.
29. Hannon Laboratory. Fastx-toolkit Hannon Laboratory Web site. http:// hannonlab.cshl.edu/fastx-toolkit/index.html. Accessed July 27, 2015.
30. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357-359..
31. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
32. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
33. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511-515.
34. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841-842.
35. Risso D, Schwartz K, Sherlock G, Dudoit S. GC-content normalization for RNA-Seq data. BMC Bioinformatics. 2011;12:480. doi: 10.1186/1471-2105-12-480.
36. Robinson MD, Smyth GK. Moderated statistical tests for assessing differences in tag abundance. Bioinformatics. 2007;23(21):2881-2887.
37. Jensen LJ, Kuhn M, Stark M, et al. STRING 8- A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412-D416.
38. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
39. Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-273.
40. Gabut M, Samavarchi-Tehrani P, Wang X, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011;147(1):132-146.
41. Goatly A, Bacon CM, Nakamura S, et al. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol. 2008;21(7):902-911.
42. Liu NQ, De Marchi T, Timmermans AM, et al. Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response. Mol Cell Proteomics. 2014;13:1814-1827.
43. Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007;67(7):3301-3309.
44. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444.
45. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; (349):247-257.
46. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer- The stable evidence. Nat Rev Clin Oncol 2010;(7):153-162.